86 related articles for article (PubMed ID: 23557424)
1. Lymphoproliferative disorders in immunocompromised individuals and therapeutic antibodies for treatment.
Yang X; Miyawaki T; Kanegane H
Immunotherapy; 2013 Apr; 5(4):415-25. PubMed ID: 23557424
[TBL] [Abstract][Full Text] [Related]
2. Immunodeficiency-associated lymphoid proliferations (ALPS, HIV, and KSHV/HHV8).
Chadburn A
Semin Diagn Pathol; 2013 May; 30(2):113-29. PubMed ID: 23537912
[TBL] [Abstract][Full Text] [Related]
3. Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder.
Pina-Oviedo S; Miranda RN; Medeiros LJ
Am J Surg Pathol; 2018 Jan; 42(1):116-129. PubMed ID: 29112013
[TBL] [Abstract][Full Text] [Related]
4. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant.
Chadburn A; Chen JM; Hsu DT; Frizzera G; Cesarman E; Garrett TJ; Mears JG; Zangwill SD; Addonizio LJ; Michler RE; Knowles DM
Cancer; 1998 May; 82(10):1978-87. PubMed ID: 9587133
[TBL] [Abstract][Full Text] [Related]
5. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.
Trahair TN; Wainstein B; Manton N; Bourne AJ; Ziegler JB; Rice M; Russell SJ
Pediatr Blood Cancer; 2008 Feb; 50(2):366-9. PubMed ID: 16732583
[TBL] [Abstract][Full Text] [Related]
7. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
[TBL] [Abstract][Full Text] [Related]
8. Lymphopenia at diagnosis predicts survival of patients with immunodeficiency-associated lymphoproliferative disorders.
Watanabe M; Kanda J; Hishizawa M; Nishikori M; Kondo T; Yamashita K; Takaori-Kondo A
Ann Hematol; 2020 Jul; 99(7):1565-1573. PubMed ID: 32436013
[TBL] [Abstract][Full Text] [Related]
9. Lymphoproliferative disorders in chronic hepatitis C.
Idilman R; Colantoni A; De Maria N; Alkan S; Nand S; Van Thiel DH
J Viral Hepat; 2004 Jul; 11(4):302-9. PubMed ID: 15230852
[TBL] [Abstract][Full Text] [Related]
10. [Methotrexate-associated lymphoproliferative disorders: clinical aspects].
Tokuhira M; Kizaki M
Rinsho Ketsueki; 2019; 60(8):932-943. PubMed ID: 31484893
[TBL] [Abstract][Full Text] [Related]
11. Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants.
Lemoine A; Pham P; Azoulay D; Saliba F; Emile JF; Saffroy R; Broet P; Bismuth H; Samuel D; Debuire B
Blood; 2001 Sep; 98(5):1332-8. PubMed ID: 11520779
[TBL] [Abstract][Full Text] [Related]
12. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.
Derby L; Czuczman MS
Future Oncol; 2011 Aug; 7(8):963-79. PubMed ID: 21823892
[TBL] [Abstract][Full Text] [Related]
13. [Differential malignant lymphoproliferative syndrome (LPS) diagnosis with flow cytometry: a study of 100 patients].
Cardile N; Sabo G; Butsch P; Brengarth E; Viollier AF; Knecht H
Praxis (Bern 1994); 2000 Jan; 89(4):143-9. PubMed ID: 10686807
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant lymphoproliferative disorders following solid-organ transplantation.
Blaes AH; Morrison VA
Expert Rev Hematol; 2010 Feb; 3(1):35-44. PubMed ID: 21082932
[TBL] [Abstract][Full Text] [Related]
15. [Inherited lymphoproliferative disorders].
Kanegane H; Hoshino A
Rinsho Ketsueki; 2019; 60(6):708-715. PubMed ID: 31281164
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA
Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated lymphoproliferative disorders.
Purtilo DT; Strobach RS; Okano M; Davis JR
Lab Invest; 1992 Jul; 67(1):5-23. PubMed ID: 1320711
[TBL] [Abstract][Full Text] [Related]
19. Cytologic findings in posttransplant lymphoproliferative disease.
Davey DD; Gulley ML; Walker WP; Zaleski S
Acta Cytol; 1990; 34(3):304-10. PubMed ID: 2343685
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant lymphoproliferative disorders after solid organ transplantation in children.
Colita A; Colita A; Moise L; Arion C; Popescu I
Chirurgia (Bucur); 2012; 107(4):431-7. PubMed ID: 23025107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
